Abstract 838P
Background
Axi-cel, a chimeric antigen receptor T-cell (CAR T) therapy evaluated in ZUMA-1, and epcor, a bispecific antibody evaluated in EPCORE NHL-1, are treatments for R/R LBCL. In the absence of a head-to-head trial, we conducted an unanchored MAIC to estimate relative treatment effects of axi-cel versus epcor in 3L+ R/R LBCL.
Methods
ZUMA-1 patient-level data were matched (using a logistic propensity score model) to baseline characteristics representing pre-specified clinically relevant prognostic factors in EPCORE NHL-1 (N=157): International Prognostic Index score, ECOG performance status, disease stage, response to last therapy, number of prior lines, primary refractoriness, LBCL subtype, and prior autologous stem cell transplant. Outcomes were objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and grade ≥3 cytokine release syndrome (G3+ CRS). Neurotoxicity was not analysed as definitions differed. Relative effects were hazard/odds ratios (HR/OR). Base case analyses included ZUMA-1 pivotal Cohorts 1+2 (C12; N=101). Scenario analyses of OS and CRS added ZUMA-1 safety Cohorts 4+6 (C1246; N=182).
Results
The effective sample size (ESS) for axi-cel was 30 in the base-case (Table). Axi-cel improved PFS (median 12.5 months) versus epcor (median 4.4 months). ORR, DOR and OS results were comparable with point estimates favoring axi-cel. A higher rate of G3+ CRS was associated with axi-cel but the difference was reduced in the scenario analysis.
Table: 838P
MAIC results
Outcome | Weighted axi-cel versus epcoritamab (95% confidence interval) | |
Base case (C12) ESS=30 | Scenario (C1246) ESS=43 | |
ORR OR | 1.55 (0.65−3.69) | N/A |
PFS HR | 0.51 (0.31−0.85) | N/A |
DOR HR | 0.84 (0.46−1.52) | N/A |
OS HR | 0.77 (0.45−1.30) | 0.67 (0.41−1.10) |
G3+ CRS OR | 5.31 (1.21−23.32) | 4.43 (1.10−17.92) |
Conclusions
Our MAIC suggests axi-cel may be more efficacious in terms of PFS versus epcor but with a higher risk of CRS G3+. Of note, median follow-up was short in EPCORE NHL-1 (10.7 months) compared to ZUMA-1 (60 months [C12] and 24 months [C46]) and differences in prior CAR T exposure could not be adjusted for (39% in EPCORE NHL-1 vs 0% in ZUMA-1).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kite, a Gilead Company.
Funding
Kite, a Gilead Company.
Disclosure
O.O. Oluwole: Financial Interests, Institutional, Advisory Role, Scientific advisory role and consultant to Kite Pharma, Allogene, CERo Therapeutics, Novartis, BlueBird Bio, Bristol Myers Squibb, National Cancer Institute, Leukemia and Lymphoma Society: Kite Pharma. M.D. Ray, H. Smith, C.L. Bellasis Spooner, A.R. Patel: Financial Interests, Personal and Institutional, Full or part-time Employment, A stockholder and current employee of Kite, a Gilead company: Kite Pharma. J.M. Chen, K. Chan, I. Zhang, S. Keeping: Financial Interests, Institutional, Full or part-time Employment, PRECISIONheor received consulting fees from Kite, a Gilead Company: PRECISIONheor. F.L. Locke: Financial Interests, Institutional, Advisory Role, Honoraria from Gilead and Pfizer; scientific advisory role and consultant for AbbVie, ADC, Curio Science, Epizyme, Gilead, Janssen, Kite, a Gilead Company, Pfizer, Nektar, Novartis, Syncopation, and TGR therapeutics: Kite Pharma.
Resources from the same session
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18